ClinicalTrials.gg
CompletedNCT00095082Updated Jan 27, 2017

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

A Phase 3 interventional study of insulin detemir and insulin glargine in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 81 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-27.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
447
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 35 studies testing Insulin Detemir in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Detemir · Diabetes Mellitus, Type 1.

Enrollment
7th of 35
447 · median 83
Started
2004
with 4 others
Phase 3
18 of 35
none open now
Registered
1st of 35
by date
Lead sponsor
25 of 35
Novo Nordisk A/S

Among the 35 studies testing Insulin Detemir in Diabetes Mellitus, Type 1, this one is the 7th largest by enrollment, is one of 5 that started in 2004, is one of 18 in phase 3, and was the 1st registered.

Diabetes Mellitus, Type 1

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 35 studies testing Insulin Detemir in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Detemir

Insulin Detemir: first FDA approval 2005 (LEVEMIR FLEXTOUCH), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies testing Insulin Detemir in Diabetes Mellitus, Type 1 as a file.
02

Study summary

This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type I diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

Keywords

  • Diabetes Mellitus, Type I
04

In context

Diabetes Mellitus, Type 1 Reclassified

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 447 is above the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetes for at least 12 months
  • Current treatment with basal-bolus insulin regimen for more than or equal to 3 months
  • less than or equal to 11.0%

Exclusion criteria

Exclusion Criteria:

  • Proliferative retinopathy or maculopathy
  • Recurrent major hypoglycaemia
  • Impaired hepatic or renal function
  • Cardiac problems or uncontrolled hypertension
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
447 participants (actual)
07

What researchers measure

Primary outcomes

  1. HbA1c

    Time frame: after 1 year trial period

Secondary outcomes

  1. Adverse events

  2. Body weight

  3. Hypoglycemia

  4. Blood glucose

  5. Insulin Treatment Satisfaction

08

Study locations

81 sites
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    Huntington Beach, California 92646, United States
  • Novo Nordisk Investigational Site
    Inglewood, California 90301, United States
  • Novo Nordisk Investigational Site
    Irvine, California 92618, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Hollywood, Florida 33021, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32216, United States
  • Novo Nordisk Investigational Site
    Lake Mary, Florida 32746, United States
  • Novo Nordisk Investigational Site
    Melbourne, Florida 32901, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33613, United States
  • Novo Nordisk Investigational Site
    Vero Beach, Florida 32960, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30318, United States
  • Novo Nordisk Investigational Site
    Idaho Falls, Idaho 83404-7596, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Topeka, Kansas 66606, United States
  • Novo Nordisk Investigational Site
    Hyattsville, Maryland 20782, United States
  • Novo Nordisk Investigational Site
    Detroit, Michigan 48235, United States
  • Novo Nordisk Investigational Site
    St. Louis, Missouri 63110, United States
  • Novo Nordisk Investigational Site
    Omaha, Nebraska 68114, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89119-6100, United States
  • Novo Nordisk Investigational Site
    Berlin, New Jersey 08009, United States
  • Novo Nordisk Investigational Site
    Sea Girt, New Jersey 08750, United States
  • Novo Nordisk Investigational Site
    Asheville, North Carolina 28803, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75235, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75390-8858, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77030, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78229, United States
  • Novo Nordisk Investigational Site
    Helsinki, 00250, Finland
  • Novo Nordisk Investigational Site
    Kuopio, 70210, Finland
  • Novo Nordisk Investigational Site
    Oulu, 90029, Finland
  • Novo Nordisk Investigational Site
    Pori, 28500, Finland
  • Novo Nordisk Investigational Site
    Vantaa, 01400, Finland
  • Novo Nordisk Investigational Site
    ANGERS cedex 09, 49033, France
  • Novo Nordisk Investigational Site
    Antibes, 06600, France
  • Novo Nordisk Investigational Site
    Brest, 29609, France
  • Novo Nordisk Investigational Site
    GRENOBLE cedex, 38043, France
  • Novo Nordisk Investigational Site
    LA ROCHELLE cedex, 17019, France
  • Novo Nordisk Investigational Site
    Mougins, 06250, France
  • Novo Nordisk Investigational Site
    TOULOUSE cedex, 31054, France
  • Novo Nordisk Investigational Site
    Alsdorf, 52477, Germany
  • Novo Nordisk Investigational Site
    Bad Kreuznach, 55545, Germany
  • Novo Nordisk Investigational Site
    Dormagen, 41539, Germany
  • Novo Nordisk Investigational Site
    Dresden, 01307, Germany
  • Novo Nordisk Investigational Site
    Flensburg, 24939, Germany
  • Novo Nordisk Investigational Site
    Friedrichsthal, 66299, Germany
  • Novo Nordisk Investigational Site
    Genthin, 39307, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 20251, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 21073, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 22607, Germany
  • Novo Nordisk Investigational Site
    Herrenberg, 71083, Germany
  • Novo Nordisk Investigational Site
    Kippenheim, 77971, Germany
  • Novo Nordisk Investigational Site
    Rehlingen-Siersburg, 66780, Germany
  • Novo Nordisk Investigational Site
    Speyer, 67346, Germany
  • Novo Nordisk Investigational Site
    St. Ingbert, 66386, Germany
  • Novo Nordisk Investigational Site
    Völklingen, 66333, Germany
  • Novo Nordisk Investigational Site
    Würzburg, 97072, Germany
  • Novo Nordisk Investigational Site
    Almere, 1315 RA, Netherlands
  • Novo Nordisk Investigational Site
    Apeldoorn, 7334 DZ, Netherlands
  • Novo Nordisk Investigational Site
    Capelle a/d IJssel, 2906 ZC, Netherlands
  • Novo Nordisk Investigational Site
    Dordrecht, 3318 AT, Netherlands
  • Novo Nordisk Investigational Site
    Leeuwarden, 8934 AD, Netherlands
  • Novo Nordisk Investigational Site
    Zoetermeer, 2725 NA, Netherlands
  • Novo Nordisk Investigational Site
    Norrköping, 601 82, Sweden
  • Novo Nordisk Investigational Site
    Stockholm, 112 81, Sweden
  • Novo Nordisk Investigational Site
    Stockholm, 182 88, Sweden
  • Novo Nordisk Investigational Site
    Umeå, 901 85, Sweden
  • Novo Nordisk Investigational Site
    Växjö, 351 85, Sweden
  • Novo Nordisk Investigational Site
    Örebro, 701 85, Sweden
  • Novo Nordisk Investigational Site
    Abergavenny, NP7 7EG, United Kingdom
  • Novo Nordisk Investigational Site
    Ayr, KA6 6DX, United Kingdom
  • Novo Nordisk Investigational Site
    Brighton, BN2 5BE, United Kingdom
  • Novo Nordisk Investigational Site
    Bristol, BS10 5NB, United Kingdom
  • Novo Nordisk Investigational Site
    Cosham, PO6 3LY, United Kingdom
  • Novo Nordisk Investigational Site
    Dundee, DD1 9SY, United Kingdom
  • Novo Nordisk Investigational Site
    Glasgow, G4 0SF, United Kingdom
  • Novo Nordisk Investigational Site
    Livingstone, EH54 6PP, United Kingdom
  • Novo Nordisk Investigational Site
    Plymouth, PL8 8DQ, United Kingdom
  • Novo Nordisk Investigational Site
    Sheffield, S5 7AU, United Kingdom
  • Novo Nordisk Investigational Site
    Watford, WD18 0HB, United Kingdom
  • Novo Nordisk Investigational Site
    Wirral, Merseyside, CH63 4JY, United Kingdom
09

References and documents

Publications

  • Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clin Ther. 2009 Oct;31(10):2086-97. doi: 10.1016/j.clinthera.2009.10.006. PubMed 19922879 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Dec 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2004
First posted
Nov 1, 2004
Start
Sep 2004
Primary completionActual
Dec 2005
CompletionActual
Dec 2005
Last update
Jan 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00095082
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 1, 2004
Start date
Sep 2004
Primary completion
Dec 2005
Completion
Dec 2005
Last update
Jan 27, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Detemir · Insulin Glargine · Insulin Aspart

Start the discussion